These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28274648)

  • 1. Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment.
    Robertson AG; Swartz MS
    J Subst Abuse Treat; 2018 Feb; 85():101-104. PubMed ID: 28274648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release naltrexone for opioid use disorder started during or following incarceration.
    Lincoln T; Johnson BD; McCarthy P; Alexander E
    J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
    Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
    Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release naltrexone opioid treatment at jail reentry (XOR).
    McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
    Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
    Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
    Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
    Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
    Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
    Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
    Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
    J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
    Cousins SJ; Crèvecoeur-MacPhail D; Kim T; Rawson RA
    J Subst Abuse Treat; 2018 Feb; 85():78-83. PubMed ID: 28291571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home-based delivery of XR-NTX in youth with opioid addiction.
    Vo HT; Burgower R; Rozenberg I; Fishman M
    J Subst Abuse Treat; 2018 Feb; 85():84-89. PubMed ID: 28867062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
    Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
    Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular extended-release naltrexone: current evidence.
    Gastfriend DR
    Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.